Replies to post #12444 on Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

Hilarious how that other stock foolishly claimed they wouldn't require phase III and now all the players are stuckholding while endless amounts of dilution reign supreme.

Yep we're so scared of a 20 cent bloated pig penny stock developing a drug pipeline that has nothing to do with IPCI whatsoever weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee

[doogdilinger]

But it is not six months away, and the company will need to raise $$ to get it done

1. No-one's ever claimed FDA approval of Rexista is 6 months away ahahahahaha!

2. IPCI themselves gave a 6 month timeline for their Rexista bioequivalence submission only...which is exactly what the FDA recently asked them to do dohhhhhhhhhhhhh

3. IPCI has already announced that they're prep'n to announce a partner on Rexista soon...so even in the unlikely event that the FDA suddenly changed its mind and asked for Rexista phase III trial, the sheer lucrative nature of such a partnership would easily cover the majority of the approximate $20M inherent costs associated with phase III trials which is such a far cry from your $50M hogwash it's laughable!

Must be great clinging to 20 cent penny stocks that have been dangling carrots and diluting 100's of millions of shares for 10 years now. IPCI's just shaking in their boots worried about that dilutive turd weeeeeeeeeeeeeeeeeeeeeeeeeeee

[doogdilinger]

Show us anywhere with a factual IPCI quote, document, press release or filing what you're claiming>>>

The reason IPCI is not being up front about this

Not that hard to follow the trail to see that it was the FDA that advised IPCI to skip phase III trials entirely...so your statement above is completely without merit in the absence of any proof of your claim that IPCI is somehow/supposedly not being up front about what the FDA has decided bwahahahahahahahhahaha

[dr_lowenstein]

you might be right in that it is a possibility that p3 will be required, but perhaps their approach upon facing that will be similar to elite, ie, take the short cut by doing and acute pain study. We know that is not 2-3 years and 25-50 million $. I do not favor that approach because it severely limits market potential but it is ONE way